At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 9 enrolled
Drug / intervention
Filgotinib +3 moredrug
Likely dose
Filgotinib 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects With Lupus Membranous Nephropathy (LMN)
In Brief
A Phase 2 clinical trial evaluating Filgotinib, Lanraplenib, and 2 other interventions for Lupus Membranous Nephropathy. Completed, enrolled 9 participants across 7 sites.
Detailed Summary
The primary objective of this study is to evaluate the efficacy of filgotinib and lanraplenib (previously GS-9876) in adults with lupus membranous nephropathy (LMN).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLupus Membranous Nephropathy
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedSep 2017
Enrollment StartOct 2017
Primary CompletionMay 2019
Study CompletionFeb 2020
TodayJul 2026
First PostedSep 18, 2017
Enrollment StartOct 6, 2017
Primary CompletionMay 3, 2019
Study CompletionFeb 3, 2020
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 8.8 years ago
Interventions
Filgotinibdrug
200 mg tablet administered orally once daily
Lanraplenibdrug
30 mg tablet administered orally once daily
Filgotinib placebodrug
Tablet administered orally once daily
Lanraplenib placebodrug
Tablet administered orally once daily